Molecular Pharmacology (USA) Ltd. engages in the development of pharmaceutical products. The company is headquartered in Leederville, Western Australia. The company went IPO on 2005-05-20. Ltd. (MPLA) is in the business of developing and commercializing an analgesic and anti-inflammatory molecule known as Tripeptofen. The Company’s over-the-counter anti-pain and anti-inflammatory products sold for the treatment of acute localized pain are based on non-steroidal anti-inflammatory drugs (NSAIDs). The licensed products include all products in all dosage forms, formulations, line extensions and package configurations using production method of metallo-polypeptide analgesic and anti-inflammatory activity as an active ingredient marketed by MPLA or its affiliates under the trade name Tripeptofen. The firm and Molecular Pharmacology Pty. Ltd. have no manufacturing facilities.
Follow-Up Questions
Molecular Pharmacology (USA) Ltd의 CEO는 누구입니까?
Jeffery Edwards은 2005부터 회사에 합류한 Molecular Pharmacology (USA) Ltd의 President입니다.
MLPH 주식의 가격 성능은 어떻습니까?
MLPH의 현재 가격은 $0.0004이며, 전 거래일에 decreased 0% 하였습니다.
Molecular Pharmacology (USA) Ltd의 주요 사업 주제나 업종은 무엇입니까?
Molecular Pharmacology (USA) Ltd은 N/A 업종에 속하며, 해당 부문은 N/A입니다
Molecular Pharmacology (USA) Ltd의 시가총액은 얼마입니까?
Molecular Pharmacology (USA) Ltd의 현재 시가총액은 $399.8K입니다
